Fractyl Health (GUTS) Total Non-Current Liabilities (2023 - 2026)
Fractyl Health (GUTS) reported Total Non-Current Liabilities of $77.4 million for Q1 2026, up 2.24% year-on-year from $75.7 million in Q1 2025, and down 30.41% quarter-over-quarter from $111.3 million in Q4 2025.
Fractyl Health (GUTS) has 4 years of Total Non-Current Liabilities data on file, last reported at $77.4 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 2.24% year-over-year to $77.4 million; the trailing twelve-month figure through Mar 2026 stood at $77.4 million (up 2.24% YoY), and the FY2025 full-year result was $111.3 million, up 41.48% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $77.4 million, down from $111.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $304.6 million in Q3 2023 and bottomed at $74.7 million in Q2 2024.
- A 4-year average of $107.3 million and a median of $78.8 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities plunged 75.2% in 2024 and surged 54.5% in 2025, its largest moves.
- Tracing GUTS's Total Non-Current Liabilities over 4 years: stood at $304.6 million in 2023, then plunged by 74.18% to $78.7 million in 2024, then surged by 41.48% to $111.3 million in 2025, then tumbled by 30.41% to $77.4 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $77.4 million, $111.3 million, and $116.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 7.32 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | 77.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.44 Mn |
| Dec 31, 2025 | 111.28 Mn |
| Sep 30, 2025 | 116.70 Mn |
| Jun 30, 2025 | 79.38 Mn |
| Mar 31, 2025 | 75.75 Mn |
| Dec 31, 2024 | 78.66 Mn |
| Sep 30, 2024 | 75.53 Mn |
| Jun 30, 2024 | 74.72 Mn |
| Mar 31, 2024 | 79.01 Mn |
| Sep 30, 2023 | 304.58 Mn |